ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

DYN Dyne Therapeutics Inc

31.75
-0.88 (-2.70%)
23 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Dyne Therapeutics Inc NASDAQ:DYN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.88 -2.70% 31.75 31.00 32.00 32.39 30.23 31.63 6,693,166 01:00:00

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

27/03/2024 12:30pm

GlobeNewswire Inc.


Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart


From Mar 2024 to May 2024

Click Here for more Dyne Therapeutics Charts.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024 at 9:50 a.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contact:

Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com 857-341-1203

1 Year Dyne Therapeutics Chart

1 Year Dyne Therapeutics Chart

1 Month Dyne Therapeutics Chart

1 Month Dyne Therapeutics Chart